Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C22H22FN3O2.C3H6O3 |
| Molecular Weight | 469.5053 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)C(O)=O.FC1=CC=C(C=C1)C(=O)CCCN2CCC(=CC2)N3C(=O)NC4=C3C=CC=C4
InChI
InChIKey=CUYSTLHETVVORS-UHFFFAOYSA-N
InChI=1S/C22H22FN3O2.C3H6O3/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28;1-2(4)3(5)6/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28);2,4H,1H3,(H,5,6)
| Molecular Formula | C22H22FN3O2 |
| Molecular Weight | 379.4274 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C3H6O3 |
| Molecular Weight | 90.0779 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: http://www.drugbank.ca/drugs/DB00450Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/droperidol.html
Sources: http://www.drugbank.ca/drugs/DB00450
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/droperidol.html
Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias. The exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine (2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well. Droperidol is used to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
CNS Activity
Sources: http://www.drugbank.ca/drugs/DB00450
Curator's Comment: Droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 Sources: http://www.drugbank.ca/drugs/DB00450 |
|||
Target ID: CHEMBL229 Sources: http://www.drugbank.ca/drugs/DB00450 |
|||
Target ID: CHEMBL240 |
32.2 nM [IC50] | ||
Target ID: CHEMBL224 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Secondary | INAPSINE Approved UseDroperidol injection is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures. Launch Date1970 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
26.6 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6.5 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
40 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
18.7 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.4 mg/kg multiple, oral Dose: 0.4 mg/kg Route: oral Route: multiple Dose: 0.4 mg/kg Sources: |
unhealthy, 2-9 years Health Status: unhealthy Age Group: 2-9 years Sources: |
Disc. AE: QT interval prolonged... AEs leading to discontinuation/dose reduction: QT interval prolonged Sources: |
8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
Other AEs: Asthenia, Chills... Other AEs: Asthenia (24.6%) Sources: Chills (3.3%) Anorexia (3.3%) Akathisia (16.4%) Anxiety (27.9%) Confusion (3.3%) Dizziness (9.8%) Dry mouth (9.8%) Nervousness (4.9%) Paresthesia (3.3%) Somnolence (24.6%) Tremor (1.6%) Pharyngitis (4.9%) Rhinitis (4.9%) Sweaty (8.2%) |
2.5 mg multiple, intravenous Dose: 2.5 mg Route: intravenous Route: multiple Dose: 2.5 mg Sources: |
unhealthy |
Disc. AE: Torsades de pointes... AEs leading to discontinuation/dose reduction: Torsades de pointes Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| QT interval prolonged | Disc. AE | 0.4 mg/kg multiple, oral Dose: 0.4 mg/kg Route: oral Route: multiple Dose: 0.4 mg/kg Sources: |
unhealthy, 2-9 years Health Status: unhealthy Age Group: 2-9 years Sources: |
| Tremor | 1.6% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Akathisia | 16.4% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Asthenia | 24.6% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Somnolence | 24.6% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Anxiety | 27.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Anorexia | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Chills | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Confusion | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Paresthesia | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Nervousness | 4.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Pharyngitis | 4.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Rhinitis | 4.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Sweaty | 8.2% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Dizziness | 9.8% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Dry mouth | 9.8% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years Health Status: unhealthy Age Group: 42 ± 10.0 years Sex: M+F Sources: |
| Torsades de pointes | Disc. AE | 2.5 mg multiple, intravenous Dose: 2.5 mg Route: intravenous Route: multiple Dose: 2.5 mg Sources: |
unhealthy |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| major | ||||
| major |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Acute dystonia by droperidol during intravenous patient-controlled analgesia in young patients. | 2002-10 |
|
| Droperidol: a cost-effective antiemetic for over thirty years. | 2002-10 |
|
| Low-dose droperidol. | 2002-09-03 |
|
| Continuum of care: stabilizing the acutely agitated patient. | 2002-09-01 |
|
| Effects of anesthesia on efferent-mediated adaptation of the DPOAE. | 2002-09 |
|
| The addition of antiemetics to the morphine solution in patient controlled analgesia syringes used by children after an appendicectomy does not reduce the incidence of postoperative nausea and vomiting. | 2002-09 |
|
| P6 acupoint injections are as effective as droperidol in controlling early postoperative nausea and vomiting in children. | 2002-08 |
|
| Effect of intravenous droperidol on intraocular pressure and retrobulbar hemodynamics. | 2002-07-13 |
|
| Dolasetron decreases postoperative nausea and vomiting after breast surgery. | 2002-07-09 |
|
| The rise and withdrawal of droperidol. | 2002-07 |
|
| Antiemetic effects of granisetron, droperidol and dexamethasone in otologic surgery. | 2002-07 |
|
| The FDA droperidol warning: is it justified? | 2002-07 |
|
| Droperidol "box warning" warrants scrutiny. | 2002-07 |
|
| FDA "black box" warning regarding use of droperidol for postoperative nausea and vomiting: is it justified? | 2002-07 |
|
| Derivative spectrophotometric determination of droperidol in presence of parabens. | 2002-06-20 |
|
| [Effects of preincisional epidural administration of lidocaine and fentanyl on postoperative pain management following hysterectomy]. | 2002-06-10 |
|
| Arrhythmias from droperidol? | 2002-06-10 |
|
| Evaluation of postural stability after low-dose droperidol in outpatients undergoing gynaecological dilatation and curettage procedure. | 2002-06 |
|
| Gateways to Clinical Trials. June 2002. | 2002-06 |
|
| Four-step local anesthesia and sedation for thoracoscopic diagnosis and management of pleural diseases. | 2002-06 |
|
| Intramuscular droperidol versus intramuscular dimenhydrinate for the treatment of acute peripheral vertigo in the emergency department: a randomized clinical trial. | 2002-06 |
|
| Droperidol--behind the black box warning. | 2002-06 |
|
| Rapid tranquillisation: time for a reappraisal of options for parenteral therapy. | 2002-06 |
|
| LC determination and degradation study of droperidol. | 2002-05-15 |
|
| Comparison of granisetron and ramosetron for the prevention of nausea and vomiting after thyroidectomy. | 2002-05 |
|
| Using imprecise probabilities to address the questions of inference and decision in randomized clinical trials. | 2002-05 |
|
| Oral ondansetron, tropisetron or metoclopramide to prevent postoperative nausea and vomiting: a comparison in high-risk patients undergoing thyroid or parathyroid surgery. | 2002-05 |
|
| Psychotropic drugs and the ECG: focus on the QTc interval. | 2002-05 |
|
| Effects of clonidine on postoperative nausea and vomiting in breast cancer surgery. | 2002-05 |
|
| Droperidol: cardiovascular toxicity and deaths. | 2002-04-02 |
|
| A placebo-controlled, randomized trial of droperidol versus metoclopramide for outpatients undergoing gynecological laparoscopy under conscious sedation. | 2002-04 |
|
| Use of sevoflurane during cardiopulmonary bypass decreases incidence of awareness. | 2002-04 |
|
| Droperidol inhibits GABA(A) and neuronal nicotinic receptor activation. | 2002-04 |
|
| Black-box warning for droperidol surprises pharmacists. | 2002-03-15 |
|
| Continuous epidural, not intravenous, droperidol inhibits pruritus, nausea, and vomiting during epidural morphine analgesia. | 2002-03 |
|
| Superior prolonged antiemetic prophylaxis with a four-drug multimodal regimen - comparison with propofol or placebo. | 2002-03 |
|
| Inapsine. Weighing the risk of fatal arrhythmias. | 2002-03 |
|
| Treatment patterns of isolated benign headache in US emergency departments. | 2002-03 |
|
| [Continuous epidural administration of droperidol to prevent postoperative nausea and vomiting]. | 2002-02 |
|
| Monocomponent chemoembolization in oral and oropharyngeal cancer using an aqueous crystal suspension of cisplatin. | 2002-01-21 |
|
| [Prophylaxis of Postoperative Nausea and Vomiting FollowingGynaecological Laparoscopy]. | 2002-01 |
|
| [Droperidol causes multifocal ventricular dysrhythmias]. | 2002-01 |
|
| A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headache. | 2002-01 |
|
| Premedication, preparation, and surveillance. | 2002-01 |
|
| Effects of sevoflurane on electrocorticography in patients with intractable temporal lobe epilepsy. | 2002-01 |
|
| The black box warning. | 2002 |
|
| Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. | 2002 |
|
| Current practices in managing acutely disturbed patients at three hospitals in Rio de Janeiro-Brazil: a prevalence study. | 2002 |
|
| Warnings strengthened on tranquilizer inapsine (Droperidol). | 2001-12-18 |
|
| Evaluation of droperidol in the acutely agitated child or adolescent. | 2001-11 |
Patents
Sample Use Guides
Dosage: The dosage should be individualized. Factors to be considered in determining dose are age, body weight, physical status, underlying pathological condition, use of other drugs, the type of anesthesia to be used, and the surgical procedure involved. Vital signs and ECG should be monitored closely.
Maximum Dosage: The maximum recommended initial dose is 2.5 mg IM or slow IV. Additional 1.25 mg doses of droperidol may be administered to achieve the desired effect. The additional doses should be administered with caution and only if the potential benefit outweighs the potential risk.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:25:41 GMT 2025
by
admin
on
Mon Mar 31 22:25:41 GMT 2025
|
| Record UNII |
09NO5N37E0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB01839MIG
Created by
admin on Mon Mar 31 22:25:41 GMT 2025 , Edited by admin on Mon Mar 31 22:25:41 GMT 2025
|
PRIMARY | |||
|
9956314
Created by
admin on Mon Mar 31 22:25:41 GMT 2025 , Edited by admin on Mon Mar 31 22:25:41 GMT 2025
|
PRIMARY | |||
|
09NO5N37E0
Created by
admin on Mon Mar 31 22:25:41 GMT 2025 , Edited by admin on Mon Mar 31 22:25:41 GMT 2025
|
PRIMARY | |||
|
100000087719
Created by
admin on Mon Mar 31 22:25:41 GMT 2025 , Edited by admin on Mon Mar 31 22:25:41 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |